Yangambin 是一种 PAF 受体拮抗剂及 UGT1A1/UGT1A3 抑制剂,对人 UGT1A1 的 IC50 为 29.7 μM、Ki 为 17.1 μM,对人 UGT1A3 的 IC50 为 56.5 μM、Ki 为 66.8 μM,可阻断 PAF 介导的反应、抑制 LTB4 介导的中性粒细胞浸润并抑制炎症事件和过敏性收缩,同时可作为中枢神经系统抑制剂降低自发活动,还具有镇痛、抗惊厥、抗利什曼原虫、血管舒张和降压作用,并可阻断电压门控 Ca2+ 通道,降低细胞中 NO、TNF-α、IL-6 和 PGE2 的产生,提高 IL-10 的产生量,对心血管损伤起到保护作用,可用于过敏、皮肤利什曼病、中枢神经系统疾病、心血管疾病的相关研究。
产品编号: MS-W03856 纯度: 98.27% CAS No.: 13060-14-5 分子式: C24H30O8 分子量: 446.49
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价

产品描述

Yangambin 是一种 PAF 受体拮抗剂及 UGT1A1/UGT1A3 抑制剂,对人 UGT1A1 的 IC50 为 29.7 μM、Ki 为 17.1 μM,对人 UGT1A3 的 IC50 为 56.5 μM、Ki 为 66.8 μM,可阻断 PAF 介导的反应、抑制 LTB4 介导的中性粒细胞浸润并抑制炎症事件和过敏性收缩,同时可作为中枢神经系统抑制剂降低自发活动,还具有镇痛、抗惊厥、抗利什曼原虫、血管舒张和降压作用,并可阻断电压门控 Ca2+ 通道,降低细胞中 NO、TNF-α、IL-6 和 PGE2 的产生,提高 IL-10 的产生量,对心血管损伤起到保护作用,可用于过敏、皮肤利什曼病、中枢神经系统疾病、心血管疾病的相关研究。

生物实验数据

生物活性 Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor with an IC50 of 29.7 μM and a Ki of 17.1 μM for human UGT1A1 and an IC50 of 56.5 μM and a Ki of 66.8 μM for human UGT1A3; it blocks PAF-mediated responses, inhibits LTB4-mediated neutrophil infiltration, and suppresses inflammatory events and allergic contraction, while also acting as a central nervous system depressant that reduces spontaneous locomotor activity and exhibiting analgesic, anticonvulsant, antileishmanial, vasodilatory, and antihypertensive effects, and it blocks voltage-gated Ca2+ channels, decreases the production of NO, TNF-α, IL-6, and PGE2 in cells, increases IL-10 production, and exerts protective effects against cardiovascular injury, making it useful for research related to allergy, cutaneous leishmaniasis, central nervous system diseases, and cardiovascular diseases.
IC50 & Target

UGT1A1

29.7 μM (IC50)

UGT1A3

56.5 μM (IC50)

UGT1A1

17.1 μM (Ki)

UGT1A3

66.8 μM (Ki)

IL-6

 

IL-10

 

LTB4

 

体外研究
(In Vitro)

Yangambin (50-200 μM; 48 h) 可强效降低 BALB/c 小鼠骨髓来源巨噬细胞内 Leishmania amazonensis (亚马逊利什曼原虫) 的活力和存活率,IC50 分别为 43.9、76 μM。
Yangambin (100 μM; 48 h) 可降低经 IFN-γ 刺激的、感染 Leishmania amazonensis 的 BALB/c 小鼠骨髓来源巨噬细胞中 NO、TNF-α、IL-6 和 PGE2 的产生,并提高 IL-10 的产生量。
Yangambin (0.1 μM-1 mM; pre-incubated before 60 mM K+Cl− stimulation) 可浓度依赖性地抑制负载 Fura-2/AM (MS-W98705) 的大鼠肠系膜动脉平滑肌细胞中由 K+Cl− 诱导的细胞内钙信号,在 30 μM 和 1 mM 浓度下抑制作用显著。
Yangambin (0.1-200 µM; 60 min) 在混合人肝微粒体中抑制 UGT1A1 和 UGT1A3 活性,IC50 值分别为 29.7 µM 和 56.5 µM。
Yangambin (2-40 µM; 30 min) 以非竞争性方式抑制混合人肝微粒体中 UGT1A1 催化的 SN-38 葡萄糖醛酸化反应,其 Ki 值为 17.1 µM。
Yangambin (5-80 µM; 30 min) 在混合人肝微粒体中竞争性抑制 UGT1A3 催化的鹅去氧胆酸 24-酰基葡萄糖醛酸化,其 Ki 值为 66.8 µM。

Cell Viability Assay

Cell Line: BALB/c mouse BMDM infected with Leishmania amazonensis (MHOM/Br88/Ba-125)
Concentration: 50, 100, 200 μM
Incubation Time: 48 h
Result: Reduced intracellular Leishmania amazonensis viability in a concentration-dependent manner.
Caused a significant reduction in parasite burden at 200 μM, with an IC50 value of 43.9 μM.
Caused a significant reduction in parasite burden at 200 μM, with an IC50 value of 76 μM.
体内研究
(In Vivo)

Yangambin (10-20 mg/kg;腹腔注射;攻击前 1 小时单次给药) 可显著抑制致敏大鼠体内抗原诱导的胸膜中性粒细胞和嗜酸性粒细胞浸润,但对渗出无抑制作用,抑制血小板减少。
Yangambin (10-20 mg/kg;腹腔注射;攻击前 1 小时单次给药) 可显著抑制正常大鼠体内抗血小板活化因子 (PAF) 诱导的胸膜嗜酸性粒细胞聚集,且在 20 mg/kg 剂量下可抑制 PAF 诱导的中性粒细胞浸润,但对渗出无影响,部分抑制血液浓缩和白细胞增多,并几乎完全阻断血小板减少。
Yangambin (20 mg/kg;腹腔注射;攻击前 1 小时单次给药) 可显著抑制正常大鼠中由 LTB4 (MS-F15386) 诱导的胸膜中性粒细胞浸润。
Yangambin (12.5-50 mg/kg;腹腔注射;单次给药) 对健康雄性瑞士小鼠具有中枢神经系统抑制活性,可降低自主活动和直立活动,延长强迫游泳不动时间,并改变高架十字迷宫参数;还可缩短戊巴比妥睡眠潜伏期,延长戊巴比妥诱导的睡眠时间。
Yangambin (10-20 mg/kg;静脉注射;单次推注) 可剂量依赖性且选择性地抑制麻醉兔体内由 PAF 诱导的心血管变化及血小板减少症。
Yangambin (1-30 mg/kg;静脉注射) 对正常血压未麻醉雄性 Wistar 大鼠可诱导剂量依赖性低血压和心动过速。

Animal Model: Wistar (both sexes, 150-200 g, sensitized subcutaneously with Ovalbumin (MS-Q48215) + aluminium hydroxide)
Dosage: 10 mg/kg; 20 mg/kg/5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: i.p.; single dose 1 h pre-challenge
Result: Failed to modify antigen-induced pleural exudation.
Significantly inhibited antigen-induced neutrophil infiltration at 4 hours at both 10 and 20 mg/kg.
Significantly inhibited antigen-induced eosinophil accumulation at 24 hours at both 10 and 20 mg/kg.
Failed to modify antigen-induced increases in hematocrit and circulating leucocyte numbers at any dose.
Dose-dependently inhibited antigen-induced thrombocytopenia at 5, 10, and 20 mg/kg.
Animal Model: Wistar (both sexes, 150-200 g)
Dosage: 10 mg/kg; 20 mg/kg
Administration: i.p.; single dose 1 hour pre-challenge
Result: Failed to modify PAF-induced pleural exudation at either dose.
Significantly inhibited PAF-induced eosinophil accumulation at 24 hours at both 10 and 20 mg/kg.
Significantly inhibited PAF-induced neutrophil infiltration at 6 hours only at the 20 mg/kg dose.
Partially inhibited PAF-induced increases in hematocrit and circulating leucocyte numbers at both 10 and 20 mg/kg.
Almost entirely prevented PAF-induced thrombocytopenia at both 10 and 20 mg/kg.
Animal Model: Wistar (both sexes, 150-200 g)
Dosage: 20 mg/kg
Administration: i.p.; single dose 1 hour pre-challenge
Result: Reduced LTB4-induced neutrophil accumulation from 1.42 × 106 cells/cavity to 0.61 × 106 cells/cavity.
Animal Model: Swiss mice (adult male, 25-30 g)
Dosage: 12.5 mg/kg; 25 mg/kg; 50 mg/kg
Administration: i.p.; single dose
Result: Reduced time of permanence in open arms to 63.5 s and 53.2 s, and percentage of time in open arms to 26.7% and 22.6% at 25 mg/kg and 50 mg/kg, respectively.
Reduced rearing to 7.6 and grooming to 1.5 at 12.5 mg/kg; reduced crossed squares to 35.0 and rearing to 6.5 at 25 mg/kg; reduced crossed squares to 29.8, rearing to 5.6, and grooming to 1.4 at 50 mg/kg.
Showed no significant changes in number of falls or time of permanence on the bar at any dose.
Reduced sleep latency to 177.0 s and prolonged sleeping time to 59.7 min at 50 mg/kg; no significant effects at 25 mg/kg.
Increased immobility time to 166.4 s and 187.6 s at 25 mg/kg and 50 mg/kg, respectively.
Animal Model: New Zealand white (either sex, 2-3 kg, pentobarbitone-anaesthetized)
Dosage: 10 mg/kg; 20 mg/kg
Administration: i.v.; single bolus
Result: Attenuated PAF (3.0 μg/kg)-induced mean arterial pressure (MAP) decrease from 49% to 30%, fully prevented PAF-induced bradycardia, and reduced PAF-induced platelet level reduction from 50% to 20% at 10 mg/kg.
Attenuated PAF (3.0 μg/kg)-induced MAP decrease from 49% to 13%, fully prevented PAF-induced bradycardia, and reduced PAF-induced platelet level reduction from 50% to 0.4% at 20 mg/kg.
Caused a short-lasting intrinsic hypotensive effect: 9.5% MAP reduction at 10 mg/kg, 23% MAP reduction at 20 mg/kg.
Failed to inhibit PAF-induced leukopaenia; PAF still caused a 62% reduction in circulating leukocytes at 10 mg/kg and 42% reduction at 20 mg/kg.
Did not alter hypotensive responses to acetylcholine, histamine, 5-hydroxytryptamine, or the hypertensive response to noradrenaline at 10 mg/kg.
Animal Model: Wistar (male, 300-350 g)
Dosage: 1 mg/kg; 5 mg/kg; 10 mg/kg; 20 mg/kg; 30 mg/kg
Administration: i.v.
Result: Induced short-lasting hypotension relative to baseline at each dose: -3.5%, -7.1%, -8.9%, -14%, and -25.5%, respectively.
Induced tachycardia relative to baseline at each dose: 5.9%, 5.9%, 8.8%, 11.6%, and 18.8%, respectively.
性状 固体
颜色 White to off-white

化学信息

分子量 446.49
分子式 C24H30O8
CAS No. 13060-14-5

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.24 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (111.98 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.2397 mL11.1985 mL22.3969 mL55.9923 mL
5 mM0.4479 mL2.2397 mL4.4794 mL11.1985 mL
10 mM0.2240 mL1.1198 mL2.2397 mL5.5992 mL
15 mM0.1493 mL0.7466 mL1.4931 mL3.7328 mL
20 mM0.1120 mL0.5599 mL1.1198 mL2.7996 mL
25 mM0.0896 mL0.4479 mL0.8959 mL2.2397 mL
30 mM0.0747 mL0.3733 mL0.7466 mL1.8664 mL
40 mM0.0560 mL0.2800 mL0.5599 mL1.3998 mL
50 mM0.0448 mL0.2240 mL0.4479 mL1.1198 mL
60 mM0.0373 mL0.1866 mL0.3733 mL0.9332 mL
80 mM0.0280 mL0.1400 mL0.2800 mL0.6999 mL
100 mM0.0224 mL0.1120 mL0.2240 mL0.5599 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础